Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease
The DOI matches its Crossref record.
Abstract
Serotonin, or 5‐hydroxytryptamine, is a naturally‐occurring vasoactive substance found primarily in the brain, enterochromaffin tissue, and blood platelets. It has diffuse cardiophysiologic effects. The multiple effects of serotonin on blood vessels can be explained by the existence of 2 serotonergic receptor subtypes (the S 1 receptor mediates vasodilation, and the S 2 receptor vasoconstriction). Serotonin via the S 2 receptor also augments the actions of several other vasoconstricting substances. Serotonin may be responsible for causing, or at least perpetuating, some forms of systemic hypertension through peripheral and central nervous system (CNS) actions. Ketanserin is a highly selective S 2‐serotonergic antagonist with additional α‐adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension. It has been shown to be more effective than placebo in treating hypertension and comparable in effectiveness to other antihypertensive drugs. Its major side effects relate to the CNS, and prolongation of the electrocardiogram QT interval has been described. Caution must be used when using ketanserin in patients receiving potassium‐ and magnesium‐losing agents, because of the risk of torsades de pointes. Ketanserin has potential utility in the treatment of eclampsia, peripheral vascular disease, carcinoid syndrome, and “shock lung.” The drug is not yet approved for clinical use in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Morrell, N. W., Adnot, S., Archer, S. L., Dupuis, J., Lloyd Jones, P., MacLean, M. R., McMurtry, I. F., Stenmark, K. R., Thistlethwaite, P. A., Weissmann, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.018 · Cited by 819
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., & Steyn, D. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub3 · Cited by 705
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., Steyn, D. W., & Henderson-Smart, D. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub2 · Cited by 263
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., Steyn, D. W., & Gialdini, C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub4 · Cited by 242
Effect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease
Sonino, N., Fava, G. A., Fallo, F., Franceschetto, A., Belluardo, P., & Boscaro, M. (2000) · Pituitary · doi:10.1023/a:1009986822146 · Cited by 41
Metadata
- Authors
- Frishman, W. H., Huberfeld, S., Okin, S., Wang, Y., Kumar, A., & Shareef, B.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1995-06
- Volume
- 35
- Issue
- 6
- Pages
- 541-572
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2127180891
- Cited by
- 89
- References
- 0
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease. https://app.cochat.ai/papers/10.1002/j.1552-4604.1995.tb05013.x
- The paper
- Frishman, W. H., Huberfeld, S., Okin, S., Wang, Y., Kumar, A., & Shareef, B. (1995). Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease. The Journal of Clinical Pharmacology. https://doi.org/10.1002/j.1552-4604.1995.tb05013.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.